Literature DB >> 8381924

A detailed autoradiographic mapping of histamine H3 receptors in rat brain areas.

H Pollard1, J Moreau, J M Arrang, J C Schwartz.   

Abstract

[3H](R)alpha-methylhistamine, a selective histamine H3-receptor ligand, was used to perform binding studies with membranes and generate light microscopic autoradiograms in sections of the rat brain. High densities of H3 receptors were found in membranes from the anterior part of the cerebral cortex, the accumbens nucleus, the striatum, the olfactory tubercles and the substantia nigra. Autoradiography of sagittal and frontal sections evidenced specific labelling in a number of gray matter areas over a very low background, as determined using thioperamide, a selective H3-receptor antagonist, as competing drug. Labelled areas were identified by comparison with adjacent Nissl-stained sections and their labelling was rated visually. H3 receptors are heterogeneously distributed among areas known to receive histaminergic projections. In the cerebral cortex, H3 receptors are present in all areas and layers, with a rostrocaudal gradient and a higher density in deep layers (laminae IV-VI). In the hippocampal formation, H3 receptors are the most abundant in the dentate gyrus and the subiculum. In the amygdaloid complex, the highest densities are found in the central, lateral and basolateral groups of nuclei. In the basal forebrain, the accumbens nucleus, the striatum, the olfactory tubercles and the globus pallidus are highly labelled. In the thalamus in which histaminergic fibres are scarce, H3 receptors are present in a rather high density, particularly in the midline, median and intralaminar groups of nuclei. In the hypothalamus, where the densest network of histaminergic fibres is found, H3 receptors occur in moderate density, being slightly more abundant in the anterior and medial part. They are also present at the level of the tuberomammillary nuclei where they may reside on histaminergic perikarya. In mesencephalon and lower brainstem, H3 receptors are abundant in the reticular part of the substantia nigra and central gray. They are present in low density in areas of noradrenergic and serotoninergic perikarya and in the spinal cord, where a faint specific labelling is detected in the gray matter, particularly in the external layers of the dorsal horn. In the cerebellum and pituitary gland, H3 receptors are scarce. Kainic acid infusions into the striatum were followed by marked local decreases in H3 receptors evidenced in both membrane binding and autoradiographic studies. Unilateral interruption of the ascending histaminergic pathways via electrocoagulation of the lateral hypothalamic area was followed by ipsilateral increase in striatal [3H](R)alpha-methylhistamine binding, a process consistent with denervation up regulation of postsynaptic H3 receptors.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8381924     DOI: 10.1016/0306-4522(93)90191-h

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  54 in total

1.  Histamine H(3) receptor-mediated inhibition of depolarization-induced, dopamine D(1) receptor-dependent release of [(3)H]-gamma-aminobutryic acid from rat striatal slices.

Authors:  J A Arias-Montaño; B Floran; M Garcia; J Aceves; J M Young
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors.

Authors:  Carla Ferrada; Estefanía Moreno; Vicent Casadó; Gerold Bongers; Antoni Cortés; Josefa Mallol; Enric I Canela; Rob Leurs; Sergi Ferré; Carme Lluís; Rafael Franco
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

3.  Histamine H(3) receptor ligands modulate L-dopa-evoked behavioral responses and L-dopa derived extracellular dopamine in dopamine-denervated rat striatum.

Authors:  Przemyslaw Nowak; Aleksandra Bortel; Joanna Dabrowska; Izabela Biedka; Grzegorz Slomian; Wojciech Roczniak; Richard M Kostrzewa; Ryszard Brus
Journal:  Neurotox Res       Date:  2008 May-Jun       Impact factor: 3.911

4.  Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function.

Authors:  Carla Ferrada; Sergi Ferré; Vicent Casadó; Antonio Cortés; Zuzana Justinova; Chanel Barnes; Enric I Canela; Steven R Goldberg; Rob Leurs; Carme Lluis; Rafael Franco
Journal:  Neuropharmacology       Date:  2008-05-16       Impact factor: 5.250

5.  Histamine H3-receptor-mediated [35S]GTP gamma[S] binding: evidence for constitutive activity of the recombinant and native rat and human H3 receptors.

Authors:  A Rouleau; X Ligneau; J Tardivel-Lacombe; S Morisset; F Gbahou; J-C Schwartz; J-M Arrang
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

Review 6.  Alzheimer's disease and age-related memory decline (preclinical).

Authors:  Alvin V Terry; Patrick M Callahan; Brandon Hall; Scott J Webster
Journal:  Pharmacol Biochem Behav       Date:  2011-02-24       Impact factor: 3.533

7.  Failed PET Application Attempts in the Past, Can We Avoid Them in the Future?

Authors:  Gang Cheng; Thomas J Werner; Andrew Newberg; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2016-12       Impact factor: 3.488

8.  Activation of peripheral and spinal histamine H3 receptors inhibits formalin-induced inflammation and nociception, respectively.

Authors:  Keri E Cannon; Rob Leurs; Lindsay B Hough
Journal:  Pharmacol Biochem Behav       Date:  2007-07-25       Impact factor: 3.533

9.  Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, potentiates neurochemical and behavioral effects of haloperidol in the rat.

Authors:  Catherine Pillot; Jordi Ortiz; Anne Héron; Sophie Ridray; Jean-Charles Schwartz; Jean-Michel Arrang
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

Review 10.  Psychopharmacological approaches to modulating attention in the five-choice serial reaction time task: implications for schizophrenia.

Authors:  Y Chudasama; T W Robbins
Journal:  Psychopharmacology (Berl)       Date:  2004-04-08       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.